13F Holdings
中文EN

VCNX VACCINEX, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1205922 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.4%
TTM net income YoY8.0%
TTM EPS YoY79.7%
Revenue 3-yr CAGR-12.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,117.3%
Net margin-3,100.5%
FCF margin-2,696.8%
EBITDA margin-3,101.8%

Returns

ROE—
ROA-598.5%
ROIC (approx.)—
Asset turnover0.19x

Leverage & solvency

Liabilities / assets195.8%
Debt / equity—
Current ratio0.50x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-78.6%
Payout ratio—
Capex / revenue3.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2024Q4*2024-12-312024Q32024-09-302024Q22024-06-302024Q12024-03-312023Q4*2023-12-312023Q32023-09-302023Q2*2023-06-302023Q12023-03-31
Income statement
Revenue$213,000$52,000$232,000$104,000$0$20,000$0$550,000
R&D expense$2.13M$3.17M$3.86M$3.38M$3.36M$4.36M$5.05M$3.81M
SG&A expense$1.47M$1.44M$2.09M$1.79M$1.63M$1.50M$2.03M$1.72M
Operating income-$3.39M-$4.55M-$5.72M-$5.07M-$4.99M-$5.83M-$7.08M-$4.99M
Interest expense————$0$0$0$0
Pretax income-$3.37M-$5.73M-$5.63M-$3.90M-$3.32M-$4.91M-$7.06M-$4.96M
Income tax$0$0$0$0$0$0$0$0
Net income-$3.37M-$5.73M-$5.63M-$3.90M-$3.32M-$4.91M-$7.06M-$4.96M
EBITDA-$3.37M-$4.53M-$5.70M-$5.05M-$4.96M-$5.80M-$7.05M-$4.96M
EPS (basic)—-2.83-3.10-2.94—-15.25-24.54-20.89
EPS (diluted)—-2.83-3.10-2.94—-15.25-24.54-20.89
Weighted avg. shares (diluted)—2.03M1.82M1.33M—322,153287,719237,527
Balance sheet
Cash & equivalents$1.11M$2.91M$233,000$2.97M$1.53M$127,000$1.91M$3.32M
Receivables$838,000$985,000$1.04M$2.77M$961,000$933,000$11,000—
Current assets$2.53M$4.76M$2.20M$7.15M$3.35M$2.21M$2.68M$4.42M
PP&E, net$65,000$82,000$106,000$110,000$136,000$164,000$177,000$207,000
Total assets$2.60M$4.85M$2.37M$7.37M$3.63M$2.56M$3.08M$4.89M
Current liabilities$5.08M$6.17M$5.23M$4.71M$5.92M$6.36M$3.38M$2.31M
Short-term debt$25,000$44,000$63,000$76,000$75,000$75,000$75,000$75,000
Long-term debt$0——$6,000$26,000$44,000$63,000$82,000
Total debt$25,000——$82,000$101,000$119,000$138,000$157,000
Total liabilities$5.08M$6.17M$5.23M$4.71M$5.94M$6.43M$3.51M$2.50M
Shareholders' equity-$2.49M-$1.32M-$2.86M$2.65M-$2.31M-$3.87M-$423,000$2.40M
Net debt-$1.08M——-$2.89M-$1.43M-$8,000-$1.77M-$3.17M
Shares outstanding2.68M2.60M—1.58M892,6174.86M65.67M54.86M
Cash flow statement
Operating cash flow-$3.93M-$3.21M-$4.42M-$4.63M-$3.59M-$3.10M-$5.51M-$5.04M
Capital expenditure$0$8,000$14,000$0$0$18,000$0$49,000
Free cash flow-$3.93M-$3.21M-$4.43M-$4.63M-$3.59M-$3.11M-$5.51M-$5.09M
Investing cash flow$0-$8,000-$14,000$0$0-$18,000$0-$49,000
Financing cash flow$2.13M$5.89M$1.69M$6.07M$5.00M$1.33M$4.09M$2.02M
Depreciation & amortization$17,000$24,000$25,000$27,000$26,500$31,000$30,000$31,000
Stock-based compensation$57,000$76,000$112,000$96,000$104,000$115,000$126,000$129,000

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.